Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations
Eyenovia provided an update on its expanded manufacturing capabilities and also announced the appointment of Bren Kern as Senior Vice President of Manufacturing and Operations.
The company announced that its new manufacturing facility in Redwood City, California is operational. The facility, which is located in close proximity to Silicon Valley-based vendors and customers, will primarily focus on Optejetmanufacturing finishing operations, including drug loading, labeling, and packaging prior to distribution.
“With our Redwood City facility now operational, Eyenovia has internal manufacturing capabilities to complement our existing contract manufacturing partners,” Michael Rowe, Chief Operating Officer of Eyenovia, said in a company news release. “As we have learned from the last few years, redundancy and additional capacity are the best insurance to making sure our Optejet products are manufactured and available on time for us and our strategic partners—Bausch+Lomb and Arctic Vision.”
Appointment of Bren Kern as SVP of Manufacturing and Operations
Eyenovia also announced the appointment of Bren Kern as the company’s new Senior Vice President of Manufacturing and Operations.
Mr. Kern has spent his career helping companies transition from research and development entities into scaled commercial manufacturing organizations. Over the past 20 years, he honed his skills by leading product optimization, supporting regulatory approvals (510K & PMA) and establishing cGMP complaint manufacturing solutions worldwide.
Reaffirm VISION-2 Timelines
Eyenovia is also reaffirming its prior timeline guidance with respect to the ongoing VISION-2 phase 3 trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in presbyopia. Enrollment in the registration-enabling study is nearing completion and the company remains on track to report topline data during the third quarter of this year.
Optejet is unique to MicroLine and is not available with any other presbyopia treatment, either currently available or in development.